Table 2: Resistance rates of community-acquired (CA) and Hospital-acquired (HA) MRSA in Tunisia.
| No. (%) of strains | ||||
| Total (n = 135) | CA-MRSA (n = 49) | HA-MRSA (n = 86) | P-value | |
| Kanamycin | 110 (81.5) | 41 (83.7) | 69 (80.2) | < 0.001 |
| Tobramycin | 46 (34.1) | 2 (4.1) | 44 (51.2) | < 0.001 |
| Gentamicin | 41 (30.4) | 1 (2) | 10 (46.5) | < 0.001 |
| Erythromycin | 60 (44.4) | 11 (22.4) | 49 (57) | < 0.001 |
| Lincomycin | 32 (23.7) | 1 (2) | 31 (36) | < 0.001 |
| Pristinamycin | 4 (2.9) | 0 | 4 (4.6) | 0.5 |
| Chloramphenicol | 23 (17) | 1 (2) | 22 (25.6) | < 0.001 |
| Tetracycline | 102 (75.6) | 37 (75.5) | 65 (75.6) | 1 |
| Ofloxacin | 47 (34.8) | 5 (10.2) | 42 (48.8) | < 0.001 |
| Rifampicin | 28 (20.7) | 2 (4.1) | 26 (30.2) | < 0.001 |
| Trimethoprim-sulfamethoxazole | 12 (8.9) | 2 (4.1) | 10 (11.6) | 0.3 |
| Fosfomycin | 3 (2.2) | 0 | 3 (3.5) | 0.6 |
| Fusidic acid | 68 (50.4) | 37 (75.5) | 31 (36) | < 0.001 |